Delaet Ingrid sold $2.6M of NBIX
Delaet Ingrid (Chief Regulatory Officer) sold 14,571 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at an average of $178.65 ($178.54–$178.72, $2.60M total) across 3 trades over 2026-07-07 to 2026-07-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only disclosed new fact is the insider’s open-market sale size, timing, and average price range under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to change the fundamental outlook without accompanying company news.
What to watch
The filing does not state reasons for the sale, and the net holdings after the transaction remain substantial, reducing signal strength.
Background
The article is an SEC Form 4 insider transaction for Neurocrine Biosciences, reported by Chief Regulatory Officer Ingrid Delaet.
Ticker impact
Neurocrine Biosciences insider Delaet Ingrid sold $2.6M of NBIX shares via a 10b5-1 plan over July 7 to July 9.
Likely limited near-term impact; any effect is more about optics than fundamentals.
The filing is a Form 4 insider transaction, explicitly marked as a pre-arranged 10b5-1 plan, and provides no additional company-specific news beyond the sale details.
Market effects
No direct sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerNEUROCRINE BIOSCIENCES INC
Company whose shares were sold by an insider under a 10b5-1 plan.
- insiderDelaet Ingrid
Chief Regulatory Officer who executed the reported open-market sales.
